These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 23849828

  • 1. Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study.
    Gerritse FL, Meulenbeld HJ, Roodhart JM, van der Velden AM, Blaisse RJ, Smilde TJ, Erjavec Z, de Wit R, Los M, NePro Study Investigators.
    Eur J Cancer; 2013 Oct; 49(15):3176-83. PubMed ID: 23849828
    [Abstract] [Full Text] [Related]

  • 2. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD, Polee M, Gerritsen W, Dalesio O, de Wit R.
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [Abstract] [Full Text] [Related]

  • 3. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
    Heidenreich A, Bracarda S, Mason M, Ozen H, Sengelov L, Van Oort I, Papandreou C, Fossa S, Hitier S, Climent MA, European investigators.
    Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
    [Abstract] [Full Text] [Related]

  • 4. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
    Du J, Yang Q, Chen XS, Tian J, Yao X.
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
    [Abstract] [Full Text] [Related]

  • 5. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
    Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K.
    Lancet Oncol; 2015 Apr; 16(4):417-25. PubMed ID: 25743937
    [Abstract] [Full Text] [Related]

  • 6. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
    Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ.
    Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
    Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G.
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219
    [Abstract] [Full Text] [Related]

  • 8. Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
    Joly F, Delva R, Mourey L, Sevin E, Bompas E, Vedrine L, Ravaud A, Eymard JC, Tubiana-Mathieu N, Linassier C, Houede N, Guillot A, Ringensen F, Cojocarasu O, Valenza B, Leconte A, Lheureux S, Clarisse B, Oudard S.
    BJU Int; 2015 Jan; 115(1):65-73. PubMed ID: 24180479
    [Abstract] [Full Text] [Related]

  • 9. A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.
    van Dodewaard-de Jong JM, de Klerk JMH, Bloemendal HJ, Oprea-Lager DE, Hoekstra OS, van den Berg HP, Los M, Beeker A, Jonker MA, O'Sullivan JM, Verheul HMW, van den Eertwegh AJM.
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1319-1327. PubMed ID: 28421240
    [Abstract] [Full Text] [Related]

  • 10. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
    Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ.
    Cancer; 2011 Jun 01; 117(11):2419-25. PubMed ID: 24048789
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials.
    Qi WX, Fu S, Zhang Q, Guo XM.
    J Chemother; 2015 Jun 01; 27(3):181-7. PubMed ID: 25492160
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Pond GR, Armstrong AJ, Galsky MD, Wood BA, Leopold L, Sonpavde G.
    Urol Oncol; 2013 Nov 01; 31(8):1457-63. PubMed ID: 22552048
    [Abstract] [Full Text] [Related]

  • 13. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
    Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G.
    J Clin Oncol; 2011 Jun 01; 29(16):2191-8. PubMed ID: 21483004
    [Abstract] [Full Text] [Related]

  • 14. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct 01; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 15. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.
    Italiano A, Ortholan C, Oudard S, Pouessel D, Gravis G, Beuzeboc P, Bompas E, Fléchon A, Joly F, Ferrero JM, Fizazi K.
    Eur Urol; 2009 Jun 01; 55(6):1368-75. PubMed ID: 18706755
    [Abstract] [Full Text] [Related]

  • 16. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
    Cho IC, Joung JY, Seo HK, Chung J, Park WS, Lee KH.
    J Cancer Res Ther; 2014 Jun 01; 10(2):251-7. PubMed ID: 25022374
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.
    Gil-Bazo I, Arévalo E, Castillo A, Zudaire ME, Carranza OE, Fusco JP, Castañón E, Collado-Gómez V, López I, Gil-Aldea I.
    Clin Genitourin Cancer; 2013 Jun 01; 11(2):78-84. PubMed ID: 23260990
    [Abstract] [Full Text] [Related]

  • 18. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
    Petrylak DP.
    Can J Urol; 2014 Apr 01; 21(2 Supp 1):77-83. PubMed ID: 24775728
    [Abstract] [Full Text] [Related]

  • 19. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
    Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, Nguyen B, Paul S, McAndrews P, Bunn PA, Kelly K.
    J Clin Oncol; 2006 Sep 20; 24(27):4405-11. PubMed ID: 16983108
    [Abstract] [Full Text] [Related]

  • 20. Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.
    Meyer A, Cygan P, Tolzien K, Galvez AG, Bitran JD, Lestingi TM, Nabhan C.
    Clin Genitourin Cancer; 2014 Apr 20; 12(2):100-5. PubMed ID: 24169494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.